FRI0410 TNF INHIBITORS REDUCE SPINAL RADIOGRAPHIC PROGRESSION IN AXIAL SPONDYLOARTHRITIS (PARTIALLY) BY DECREASING DISEASE ACTIVITY

Background Recent observational data suggest that TNFi reduce spinal radiographic progression in radiographic axial spondyloarthritis (r-axSpA) mostly by inhibiting disease activity1. Yet, resolution on the controversial effect of TNFi on structural progression is yet to be achieved. Objectives To investigate whether in r-axSpA TNFi have an indirect (through ASDAS) and/or direct effect on spinal radiographic progression. Methods Patients (pts) with axial spondyloarthritis (axSpA) fulfilling the modified New York criteria (mNY) were included in this prospective, observational cohort (ALBERTA FORCAST). Clinical and imaging data were collected at baseline and every 2 years up to 10 years of follow-up. Radiographs of the spine were independently scored by 2 central readers and one adjudicator (if disagreement), with known chronological order but blinded to clinical data, using the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS). The indirect effect of TNFi on mSASSS progression was evaluated by testing the interaction between TNFi and ASDAS at the start of each 2-year interval (t). If significant (p Results In total, 314 pts were included [74% males, mean symptom duration 17.8 (SD 11.7) years, 83% HLA-B27 positive and 7% previously treated with ≥1 TNFi]. The interaction between ASDAS and TNFi at t was significant (p=0.10). A gradient was seen for the effect of ASDAS at t on mSASSS at t+1, which was more than 2 times higher in patients never treated with TNFi (β (95% CI): 0.41 (0.13; 0.68) compared to those always treated [β (95% CI): 0.16 (0.00; 0.31)] (Figure), showing that treatment with TNFi diminishes the effect of ASDAS on mSASSS. In addition to the indirect effect, TNFi also directly associated with less mSASSS progression: Pts receiving TNFi at t had on average 0.87 mSASSS-units less on t+1 compared to those not treated [β (95% CI): -0.85 (-1.35; -0.35)] and this was noted independently of ASDAS. Importantly, this effect remained significant after PS-adjustment [β (95% CI): -0.80 (-1.37; -0.22)]. Conclusion This data is in in agreement with previous evidence showing that treatment with TNFi limits spinal radiographic progression in pts with r-axSpA by decreasing disease activity. Additionally, a direct effect of TNFi reducing mSASSS progression, and independent of ASDAS inflammation, is also seen suggesting that other mechanisms also contribute to the structural effect of TNFi. References [1] Molnar C, et al. Ann Rheum Dis2018;77:63-69. Disclosure of Interests Alexandre Sepriano: None declared, Sofia Ramiro Grant/research support from: MSD, Consultant for: AbbVie, Lilly, MSD, Novartis, Pfizer, Sanofi, Speakers bureau: AbbVie, Lilly, MSD, Novartis, Pfizer, Sanofi, Stephanie Wichuk: None declared, Praveena Chiowchanwisawakit: None declared, Terrie MacCosham: None declared, Joel Paschke: None declared, Desiree van der Heijde Consultant for: AbbVie, Amgen, Astellas, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Daiichi, Eli-Lilly, Galapagos, Gilead, GlaxoSmithKline, Janssen, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi, Takeda, Union Chimique Belge, Robert B.M. Landewe: None declared, Walter P. Maksymowych Grant/research support from: Abbvie, Novartis, Pfizer, Consultant for: Abbvie, Boehringer, Celgene, Galapagos, Lilly, Novartis, Pfizer, UCB, Speakers bureau: Abbvie, Boehringer, Celgene, Galapagos, Lilly, Novartis, Pfizer, UCB